NRXP Stock Risk & Deep Value Analysis

NRX Pharmaceuticals Inc

Healthcare • Biotechnology

DVR Score

3.0

out of 10

Risk Trap

The Bottom Line on NRXP

We analyzed NRX Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran NRXP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 27, 2026•Run Fresh Analysis →•

Get notified when NRXP moves

Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.

📈NRXP Performance Overview3yr weekly

📊

Unlock NRXP Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

NRXP Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Medium

About NRX Pharmaceuticals Inc (NRXP)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

NRXP Deep Value Analysis

NRXP continues to possess a high-impact asset in NRX-101 for Bipolar Depression with Suicidal Ideation, bolstered by Breakthrough Therapy designation and targeting a significant unmet medical need. This offers substantial market potential for future leadership within its niche. However, the company's financial state remains critically precarious, characterized by chronic low cash reserves, a high burn rate, and an unsustainable reliance on highly dilutive capital raises. Past regulatory setbacks with ZYESAMI also contribute to the risk profile. Despite the promising scientific foundation, the severe financial headwinds and ongoing dilution make a realistic 10x return for *existing* shareholders within 3-5 years highly improbable. No material changes observed since the last analysis (2026-03-19) justify a significant score adjustment, therefore the score remains consistent at 30/100.

NRXP Research Sources

Research sources

No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.

For educational context only. Not financial advice.

NRXP Red Flags & Warning Signs

⚠
Negative or inconclusive NRX-101 clinical trial results
⚠
Further highly dilutive equity raises
⚠
Regulatory setbacks or delays for NRX-101

Unlock NRXP Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

NRXP Competitive Moat Analysis

Moat Rating

Narrow

Moat Trend

Expanding (if NRX-101 continues positive clinical progress) but highly fragile.

Moat Sources

1 Identified

Intangible Assets (Patents for NRX-101, regulatory designations like Breakthrough Therapy)

The moat is dependent on successful clinical trials, robust patent protection for NRX-101, and the ability to differentiate from current and future treatments. It could be durable if NRX-101 gains market exclusivity and strong adoption.

NRXP Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

NRXP Catalysts & Growth Drivers

Near-Term (0-6 months)

•Update on NRX-101 Phase 3 clinical trial progress (timing and interim data, if applicable)
•Announcement of a non-dilutive funding mechanism or strategic partnership

Medium-Term (6-18 months)

•Top-line data readout from NRX-101 Phase 3 trial (potential Q4 2026 / Q1 2027)
•Potential NDA (New Drug Application) submission for NRX-101 (post-successful Phase 3)

Long-Term (18+ months)

•Potential FDA approval and commercial launch of NRX-101
•Expansion of NRX-101 indications or development of pipeline assets

Catalysts & Growth Drivers

NRXP Bull Case: What Could Go Right

✓
Positive Phase 3 data for NRX-101 and progression towards NDA submission
✓
Successful execution of non-dilutive financing or significant partnership
✓
Improvement in cash runway and reduction in quarterly burn rate

Bull Case Analysis

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for NRX Pharmaceuticals Inc (NRXP)?

As of March 27, 2026, NRX Pharmaceuticals Inc has a DVR Score of 3.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What ticker symbol does NRX Pharmaceuticals Inc use?

NRXP is the ticker symbol for NRX Pharmaceuticals Inc. The company trades on the NCM.

What is the risk level for NRXP stock?

Our analysis rates NRX Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the NRXP DVR analysis updated?

Our AI-powered analysis of NRX Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 27, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.